RAINBOW: A GLOBAL, PHASE 3, DOUBLE-BLIND STUDY OF RAMUCIRUMAB (RAM) PLUS PACLITAXEL (PTX) VERSUS PLACEBO (PL) plus PTX IN THE TREATMENT OF ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA FOLLOWING DISEASE PROGRESSION ON FIRST-LINE PLATINUM- AND FLUOROPYRIMIDINE-CONTAINING COMBINATION THERAPY: A SUBGROUP ANALYSIS OF WESTERN POPULATION

被引：0

作者：

Wilke, Hansjochen ^{[1
]}

Clingan, Philip ^{[2
]}

Ananda, Sumi ^{[3
]}

Kurteva, Galina ^{[4
]}

Suuroja, Tiit ^{[5
]}

Folprecht, Gunnar ^{[6
]}

Beny, Alexander ^{[7
]}

Pastorelli, Davide ^{[8
]}

Cesas, Alvydas ^{[9
]}

Nowecki, Zbigniew ^{[10
]}

Toganel, Cornelia ^{[11
]}

Bodoky, Gyoergy ^{[12
]}

Lipatov, Oleg ^{[13
]}

Miron, Maria Limon ^{[14
]}

Cunningham, David ^{[15
]}

Cummins, Sebastian ^{[16
]}

Wainberg, Zev ^{[17
]}

Ko, Andrew ^{[18
]}

Emig, Michael ^{[19
]}

Chandrawansa, Kumari ^{[20
]}

van Cutsem, Eric ^{[21
]}

机构：

[1] Kliniken Essen Mitte, Essen, Germany

[2] Southern Med Day Care Ctr, Wollongong, NSW, Australia

[3] Western Hlth, Melbourne, Vic, Australia

[4] Specialised Hosp Act Treatment Oncol, Sofia, Bulgaria

[5] North Estonia Med Ctr, Tallinn, Estonia

[6] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[7] Rambam Hlth Care Campus, Haifa, Israel

[8] Ist Oncol Veneto IRCCS, Padua, Italy

[9] Klaipeda Univ Hosp, Klaipeda, Lithuania

[10] Ctr Onkol Inst M Sklodowskiej Curie, Warsaw, Poland

[11] Spitalul Clin Judetean Mures, Targu Mures, Romania

[12] St Laszlo Hosp, Dept Oncol, Budapest, Hungary

[13] Republican Clin Oncol Dispensary, Ufa, Russia

[14] HUV Rocio, Seville, Spain

[15] Royal Marsden Hosp, London SW3 6JJ, England

[16] Royal Surrey Cty Hosp, Guildford, Surrey, England

[17] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[18] Univ Calif San Francisco, San Francisco, CA 94143 USA

[19] Eli Lilly & Co, Homburg, Germany

[20] Eli Lilly & Co, Indianapolis, IN 46285 USA

[21] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 10卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

362

引用

页码：171 / 171

页数：1

共 44 条

[1] RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy-An age-group analysis
Muro, Kei
Bodoky, Gyorgy
Cesas, Alvydas
Chao, Yee
Clingan, Philip
Hironaka, Shuichi
Komatsu, Yoshito
Kurteva, Galina Petrova
Lipatov, Oleg N.
Nishina, Tomohiro
Oh, Sang Cheul
Ohtsu, Atsushi
Shimada, Yasuhiro
Sugimoto, Naotoshi
Van Cutsem, Eric
Carlesi, Roberto
Chandrawansa, Kumari
Wilke, Hansjochen
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[2] RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum-and fluoropyrimidine-containing combination therapy-Efficacy analysis in Japanese and Western patients.
Hironaka, Shuichi
Shimada, Yasuhiro
Sugimoto, Naotoshi
Komatsu, Yoshito
Nishina, Tomohiro
Yamaguchi, Kensei
Segawa, Yoshihiko
Omuro, Yasushi
Tamura, Takao
Doi, Toshihiko
Yukisawa, Seigo
Yasui, Hirofumi
Nagashima, Fumio
Gotoh, Masahiro
Esaki, Taito
Emig, Michael
Chandrawansa, Kumari
Muro, Kei
Wilke, Hansjochen
Ohtsu, Atsushi
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.
Xu, Rui-hua
Zhang, Yan-Qiao
Pan, Hongming
Feng, Ji Feng
Zhang, Tao
Liu, Tianshu
Qin, Yanru
Han, Rubing
Zhang, Wanli
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[4] RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)
Wilke, Hansjochen
Van Cutsem, Eric
Oh, Sang Cheul
Bodoky, Gyorgy
Shimada, Yasuhiro
Hironaka, Shuichi
Sugimoto, Naotoshi
Lipatov, Oleg N.
Kim, Tae-You
Cunningham, David
Ohtsu, Atsushi
Rougier, Philippe
Emig, Michael
Carlesi, Roberto
Chandrawansa, Kumari
Muro, Kei
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[5] REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.
Fuchs, Charles S.
Tomasek, Jiri
Cho, Jae Yong
Tomasello, Gianluca
Goswami, Chanchal
dos Santos, Lucas Vieira
Aprile, Giuseppe
Ferry, David
Melichar, Bohuslav
Tehfe, Mustapha Ali
Tehfe, All
Topuzov, Eldar
Zalcberg, John Raymond
Chau, Ian
Tabernero, Josep
Hsu, Yanzhi
Schwartz, Jonathan D.
Koshiji, Minori
Safran, Howard
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic factors.
Wilke, Hansjochen
Van Cutsem, Eric
Oh, Sang Cheul
Bodoky, Gyorgy
Shimada, Yasuhiro
Hironaka, Shuichi
Sugimoto, Naotoshi
Lipatov, Oleg N.
Kim, Tae-You
Cunningham, David
Rougier, Philippe
Emig, Michael
Carlesi, Roberto
Chandrawansa, Kumari
Muro, Kei
Ohtsu, Atsushi
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
Kensei Yamaguchi
Kazumasa Fujitani
Fumio Nagashima
Yasushi Omuro
Nozomu Machida
Tomohiro Nishina
Toshiko Koue
Mika Tsujimoto
Kaijiro Maeda
Taroh Satoh
Gastric Cancer, 2018, 21 : 1041 - 1049
[8] Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
Yamaguchi, Kensei
Fujitani, Kazumasa
Nagashima, Fumio
Omuro, Yasushi
Machida, Nozomu
Nishina, Tomohiro
Koue, Toshiko
Tsujimoto, Mika
Maeda, Kaijiro
Satoh, Taroh
GASTRIC CANCER, 2018, 21 (06) : 1041 - 1049
[9] The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
Shah, Manish A.
Shitara, Kohei
Lordick, Florian
Bang, Yung-Jue
Tebbutt, Niall C.
Metges, Jean-Philippe
Muro, Kei
Shen, Lin
Tjulandin, Sergei
Hays, John L.
Xu, Rui-hua
Fontaine, Marilyn
Brooks, Emily
Xu, Bo
Li, Wei
Li, Chiang
Borodyansky, Laura
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] QUALITY-OF-LIFE (QOL) RESULTS FROM THE PHASE 3 RAINBOW-ASIA STUDY OF RAMUCIRUMAB PLUS PACLITAXEL (RAM/PTX) VERSUS PLACEBO PLUS PACLITAXEL (PBO/PTX) IN PATIENTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (AGC)
Xu, R.
Shen, L.
Qin, Y.
Qin, S.
Yin, X.
Liu, B.
Tanasanvimon, S.
Zhou, C.
Zhang, W.
Zhou, L.
VALUE IN HEALTH, 2021, 24 : S21 - S21

← 1 2 3 4 5 →